Autonomix Medical (AMIX) reported QQ4 2025 results with no reported revenue across the latest four-quarter window, underscoring the company’s continued status as a development-stage medical device company focused on peripheral nervous system sensing technologies. In the quarter, R&D and G&A expenses combined totaled $3.252 million, driving an EBITDA of -$3.097 million and a net loss of -$3.191 million. Diluted earnings per share stood at -$1.81 on 1.766 million weighted-average shares. While the company remains far from profitability, the YoY metric movements show a mixed profitability signal: operating income declined by 34.6% year-over-year and by 18.4% quarter-over-quarter, whereas net income appeared to improve year-over-year by roughly 41% but declined about 18% sequentially. The absence of revenue and the sizable burn reinforces the need for external funding or strategic milestones (regulatory approvals, clinical data readouts, or partnerships) to extend the company’s runway.
Looking ahead, Autonomix’s trajectory hinges on securing pivotal product and regulatory milestones, potential licensing deals, or collaborations that could monetize its catheter-based microchip-enabled sensing platform. In the near term, investors should monitor liquidity runway, any new capital raising plans, and any updates to product development timelines or clinical validation outcomes. Given the pre-revenue status and concentrated R&D intensity, the stock remains high-risk and highly sensitive to capital market conditions and regulatory progress.